First participant receives Evategrel in CureGene’s trial

CureGene Pharmaceutical has dosed the first participant in its pivotal clinical trial of Evategrel, a next-generation antiplatelet therapy, in the US. The ongoing registrational trial will assess the efficacy and safety of Evategrel in both injection and oral capsule forms. The trial will compare Evategrel to clopidogrel in participants with acute coronary syndrome and other related conditions. Credit: PanuShot / Shutterstock.com. CureGene Pharmaceutical has dosed the first participant in its pivotal clinical trial of Evategrel (CG-0255), a next-generation antiplatelet therapy, in the US. This marks a significant milestone in the clinical development of Evategrel and advances CureGene’s plans to submit…

Source: Clinical Trials Arena